Canopy Growth gets a ‘Speculative Buy’ rating with a 57% upside target and announces a 2026 leadership transition at its Storz & Bickel vaporizer subsidiary to drive US expansion.
Friday brought a dual focus for Canopy Growth Corporation, as the cannabis company navigated a new analyst initiation and a planned leadership transition at its subsidiary, Storz & Bickel. These developments collectively signal a firm in the midst of strategic repositioning.
Leadership Transition at Key Subsidiary
A significant management change is scheduled for April 1, 2026, at Canopy Growth’s vaporizer technology unit, Storz & Bickel. David Männer is set to assume the role of Managing Director, succeeding co-founder Jürgen Bickel. Bickel, who helped establish the company in 2001, will be stepping down after a 25-year tenure at its helm. Männer brings 14 years of experience within the organization, most recently serving as Deputy Managing Director.
In a statement, Canopy Growth CEO Luc Mongeau indicated the move is designed to catalyze further innovation and accelerate the brand’s expansion efforts in the United States. Storz & Bickel holds ISO 13485 certification as a medical device manufacturer—a quality designation that maintains relevance within the regulated medical cannabis sector.
Should investors sell immediately? Or is it worth buying Canopy Growth?
Analyst Coverage Initiates with Bullish Stance
In a separate development, the equity research team at Canaccord Genuity commenced coverage on Canopy Growth shares. The firm issued a “Speculative Buy” rating alongside a CA$2.00 price target. Based on the previous closing price of CA$1.27, this target implies a potential upside of approximately 57 percent.
This optimistic assessment aligns with the broader analyst consensus, which currently stands at “Moderate Buy.” This consensus is supported by two “Buy” recommendations and one “Hold” recommendation. The average price target among covering analysts is CA$1.97, with a range spanning from CA$1.40 to CA$2.50. Notably, ATB Cormark recently upgraded its rating to “Sector Perform,” though it maintains a more conservative price objective of CA$1.40.
Market Reaction and Forward Outlook
Canopy Growth’s equity closed Friday’s session with a decline of 0.78 percent. Whether the positive analyst sentiment and the reshaped leadership at Storz & Bickel will translate into medium-term traction remains an open question. A key factor will be the performance of demand in the vaporizer technology segment, which continues to operate under the pressure of a high-interest-rate environment.
Ad
Canopy Growth Stock: New Analysis – 28 March
Fresh Canopy Growth information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.
![i’m-nervous,-too!-[part-2]](https://10xwealthreport.com/wp-content/uploads/2026/03/177042-im-nervous-too-part-2-1568x784.jpg)
